Fast Delivery Factory Price 99% Purity Rosuvastatin Pharmaceutical API CAS 287714-41-4

• Product Name: Rosuvastatin
• CAS No.: 287714-41-4
• Molecular Formula: C22H28FN3O6S
• Molecular Weight: 481.54
• Melting Point: 161.9 °C
• Boiling Point: 745.6±70.0 °C(Predicted)
• Model NO.: Rosuvastatin
• Density: 1.368±0.06 g/cm3(Predicted)
• Transport Package: Foil Bag
• Specification: 1kg /bag
• Trademark: SENWAYER
• Origin: China
• HS Code: 2937500000
• Production Capacity: 1000kg/Month

Product Description

 Fast Delivery Factory Price 99% Purity Rosuvastatin Pharmaceutical API CAS 287714-41-4

Product name	Rosuvastatin
CAS number	287714-41-4
Molecular formula	C22H28FN3O6S
Molecular weight	481.54

Appearance	White Powder
Purity	99.0%
Description	Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM. IC50 Value: 11 nM [1]Target: HMG-CoA reductasein vitro: Rosuvastatin is relatively hydrophilic and is highly selective for hepatic cells; its uptake is mediated by the liver-specific organic anion transporter OATP-C. Rosuvastatin is a high-affinity substrate for OATP-C with apparent association constant of 8.5 μM [2]. Rosuvastatin inhibits cholesterol biosynthesis in rat liver isolated hepatocytes with IC50 of 1.12 nM. Rosuvastatin causes approximately 10 times greater increase of mRNA of LDL receptors than pravastatin [1]. Rosuvastatin (100 μM) decreases the extent of U937 adhesion to TNF-α-stimulated HUVEC. Rosuvastatin inhibits the expressions of ICAM-1, MCP-1, IL-8, IL-6, and COX-2 mRNA and protein levels through inhibition of c-Jun N-terminal kinase and nuclear factor-kB in endothelial cells [3].in vivo: Rosuvastatin (3 mg/kg) daily administration for 14 days decreases plasma cholesterol levels by 26% in male beagle dogs with normal cholesterol levels. In cynomolgus monkeys, Rosuvastatin decreases plasma cholesterol levels by 22% [1]. Rosuvastatin (20 mg/kg/day) administration for 2 weeks, significantly reduces very low-density lipoproteins (VLDL) in diabetes mellitus rats induced by Streptozocin [4]. Rosuvastatin shows antiatherothromhotic effects in vivo. Rosuvastatin (1.25 mg/kg) significantly inhibits thrombin-induced transmigration of monocvtes across mesenteric venules via inhibition of the endothelial cell surface expression of P-selectin, and increases the basal rate of nitrc oxide in aortic segments by 2-fold times.

 

It is clinically used for the treatment of primary hypercholesterolemia, familial hypercholesterolemia and lipid disorders caused by other reasons.